Cravit Ophthalmic en es it fr

Categorie

Cravit Ophthalmic Les marques, Cravit Ophthalmic Analogs

Cravit Ophthalmic Les marques melange

  • No information avaliable
  • Cravit Ophthalmic Formule chimique

    C36H42F2N6O9

    Cravit Ophthalmic RX lien

    http://www.rxlist.com/cgi/generic2/quixin.htm

    Cravit Ophthalmic FDA fiche

    Cravit_Ophthalmic FDA

    Cravit Ophthalmic msds (fiche de securite des materiaux)

    Cravit Ophthalmic Synthese de reference

    Mitscher, Lester A. et al;. J. Med;. 30, 12, 2283-2286 (1987)

    Cravit Ophthalmic Poids moleculaire

    740.751 g/mol

    Cravit Ophthalmic Point de fusion

    No information avaliable

    Cravit Ophthalmic H2O Solubilite

    Insolubles

    Cravit Ophthalmic Etat

    Solid

    Cravit Ophthalmic LogP

    1.268

    Cravit Ophthalmic Formes pharmaceutiques

    Tablet; liquide; Solution

    Cravit Ophthalmic Indication

    Pour le traitement de la conjonctivite bactérienne causée par des souches sensibles des micro-organismes suivants: l'espèce Corynebacterium, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, , Streptococcus (Groupes C / F / G), le groupe viridans streptocoques, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

    Cravit Ophthalmic Pharmacologie

    La lévofloxacine, un anti-infectieux des fluoroquinolones, est optiquement actif L-isomère de l'ofloxacine. La lévofloxacine est utilisé pour traiter la conjonctivite bactérienne, sinusite, bronchite chronique, pneumonie d'origine communautaire et la pneumonie provoquée par la pénicilline des souches résistantes de Streptococcus pneumoniae, les infections structure de la peau et la peau, des infections urinaires compliquées et pyélonéphrite aiguë.

    Cravit Ophthalmic Absorption

    L'absorption de l'ofloxacine après doses uniques ou multiples de 200 à 400 mg est prévisible, et la quantité de médicament absorbée augmente proportionnellement avec la dose.

    Cravit Ophthalmic Toxicite

    Les effets secondaires incluent la désorientation, étourdissements, somnolence, bouffées de chaleur et de froid, nausées, troubles d'élocution, de l'enflure et un engourdissement dans le visage

    Cravit Ophthalmic Information pour les patients

    PATIENT INFORMATION

    While taking ofloxacin patient should be advised to:

    � to drink fluids liberally;

    � that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;

    � that ofloxacin can be taken without regard to meals;

    � that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;

    � to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;

    � that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction

    � to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;

    � that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;

    � that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.

    Cravit Ophthalmic Organismes affectes

    Bactéries entériques et d'autres eubactéries